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ABSTRACT 
Background: HPV infection is commonly found in the anogenital tract of men and women with and without clinical 
lesions. The aetiological role of HPV infection among women with cervical cancer is well-established, and there is 
growing evidence of its central role in other anogenital sites. The key to preventing human papillomavirus (HPV) infection 
is education and immunization of youth. We investigated the awareness and knowledge of HPV infection/HPV vaccine 
and potential acceptability to HPV vaccine and explore the acceptability of vaccination among the medical students in 
West Bengal. Methodology: A cross sectional study was conducted in Jan-Feb 2019 to know the level of knowledge, 
awareness and attitude about various aspects of HPV infection and vaccine among medical students in two different 
medical colleges of West Bengal. There were 200 medical students between 18‑25 years who participated in the study, out 
of which 137 were males and 63 were females. A self-administered questionnaire designed for the study was given to the 
students. Students were educated on the purpose of the study and contents and completion of questionnaire. Results: 
Majority of the students were well aware of the viral etiology of cervical cancer. The survey sample consisted of 200 
medical students aged between 18‑25 years with a mean age of 21.8 ± 1.57 years. There were 133 (66.5%) males and 67 
(33.5%) females studying in second or third year of M.B.B.S and all of them were unmarried. Almost all the students 
heard about of HPV. Majority of the students (52%) thought lack of access and knowledge was the most important 
obstacle for receiving HPV vaccination followed by doubt about effectiveness. The most common source of information 
for our study population was teachers and textbooks (94%) followed by classroom teaching 43.5%. Other sources of 
information include internet (31%), news papers and television (10.5%) and friends (4.5%). Majority of the study group 
(99%) like to update their knowledge by experts. About 14.2% of our study participants had been questioned by friends 
and relatives regarding HPV vaccination. Conclusion: To conclude gaps in knowledge regarding HPV infection and 
vaccination existed amongst the medical students and a more integrated teaching regarding HPV carcinogenesis, 
vaccination and cervical cancer needs to be introduced. 
Keywords: Human papilloma virus infection, HPV vaccine, Cervical cancer, Awareness and knowledge, Medical 
students 
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INTRODUCTION 
The human papillomavirus (HPV) is a DNA tumor 
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virus that causes epithelial proliferation at cutaneous 
and mucosal surfaces. It is the most common sexually 
transmitted viral infection and studies estimate that 
globally 50-80% of ever sexually active men and 
women are infected with the virus at least once during 
their lifetimes.[1,2] HPVs have been classified into low 
and high risk types depending on their oncogenic 
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potentials. Anogenital infections with high-risk HPV 
types (types 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 
58, 59, 66, 68, and 70) predispose men and women to 
the development of preinvasive and invasive disease in 
cervix, vulva, anus and penis.[3] Infection with 
oncogenic human papillomavirus (HPV) types is the 
primary cause of cervical cancer, the second most 
common cancer among women worldwide.[4] Cervical 
cancer is one of the leading causes of death among 
women in India. The estimated age-standardized 
incidence rate was 22.9/100,000 women in 2012. India 
contributed to one-fourth of the global burden of 
cervical cancer in 2000. [5]There are two types of HPV 
vaccines, bivalent and quadrivalent; both are licensed 
and available in India. The vaccines are already in use 
in the private sector. However, HPV vaccine is yet to 
be included in the immunization programme in India. 
[6]Quadrivalent vaccine protects against four HPV types 
(6, 11, 16 and 18) and the bivalent vaccine protects 
against two HPV types 16 and 18.[7] A recently 
introduced nonavalent (nine valent) vaccine protects 
against five HPV types 31, 33, 45, 52 and 58 in 
addition to the types covered in quadrivalent vaccine. 
All three available vaccines (bivalent, quadrivalent, 
and nonavalent) are administered intramuscularly. [8] 
The recently approved quadrivalent (types 6, 11, 16, 
and 18) HPV vaccine targets the HPV strains 
responsible for approximately 70% of cervical cancers 
and 90% of genital warts. It is also effective in 
reducing the incidence of HPV-related conditions, 
including cervical intraepithelial neoplasia (CIN) 
grades I, II, and III; adenocarcinoma in situ (AIS); 
vulvar and vaginal neoplasia; and genital warts, 
especially when given prior to exposure to HPV.[1]The 
HPV virus is transmitted through direct skin-to-skin 
contact. Although infection is most often spread 
through penetrative vaginal or anal intercourse, other 
types of sexual contact can transmit HPV, and infection 
has been reported in self-reported “virgins.’’[1]  
 
MATERIAL AND METHOD 
 
A cross sectional study was conducted in Jan-Feb 2019 
to know the level of knowledge, awareness and attitude 
about various aspects of HPV infection and vaccine 
among medical students in two different medical 
colleges of West Bengal. There were 200 medical 
students between 18‑25 years who participated in the 
study, out of which 137 were males and 63 were 
females. A self-administered questionnaire designed 
for the study was given to the students. Students were 
educated on the purpose of the study and contents and 
completion of questionnaire. They were told that the 
data was confidential and for research purpose only. 
Verbal consent was taken from the participants. The 
returned questionnaires were checked for completeness 
and consistency. The participants were assured of 
anonymity and confidentiality and were requested to 
complete questionnaire regarding HPV infections and 
HPV vaccine. Improperly filled questionnaires are 
excluded. A total of 200 questionnaires were used for 
analysis. Data entry and analysis of results was done 
using Microsoft Excel[Table 1]. 
 
RESULTS 
Table 1: Knowledge and awareness about HPV virus, infection and risk factors [n=200] 
1. What is the HPV?   
a) Virus  
b) Bacteria  
c) Fungus  
d) Others  
e) Don’t Know  
 
a) 100% 
b) 0 
c) 0 
d) 0 
e) 0 
2. What is the transmission route of HPV?  
a) Sexual transmission 
b) Mother to newborn transmission 
c) Transplacental transmission 
d) Others  
e)  Don’t Know 
 
a) 196 (98%) 
b) 41 (20.5%) 
c) 37 (18.5%) 
d) 2 (1%) 
e) 2 (1%) 
3. Can the HPV virus cause cervical cancer?  
a) Yes   
b) No  
c) Don’t Know 
 
a) 188 (94%) 
b) 7 (3.5%) 
c) 5 (2.5%) 
4. High-risk HPV is more likely to cause cancer. Which one? 
a) Cervical cancer 
b) Oral cancer 
c) Anal cancer,  
d) Vulvar and vaginal cancers in women 
 
a) 188 (94%) 
b) 3 (1.5%) 
c) 3 (1.5%) 
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e) Penile cancer in men 
f) Others  
d) 76 (38%) 
e) 02 (1%) 
f) Nil  
5. What are the main hazards of HPV infection for female? 
  
 
a) Cervical, vulvar, vaginal, and anal cancer 49 (24.5%) 
b) Genital warts (condyloma acuminata) 186 (93%) 
c) Cervical intraepithelial neoplasia (CIN) and Cervical 
adenocarcinoma in situ 87(43.5%) 
d) Vulvar intraepithelial neoplasia (VIN) 37 (18.5%) 
e) Vaginal intraepithelial neoplasia (VaIN) 23 (11.5%) 
f) Anal intraepithelial neoplasia 11 (5.5%) 
6. What are the main hazards of HPV infection for male?  a) Anal cancer 13 (6.5%) 
b) Genital warts (condyloma acuminata) 111 (55.5) 
c) Anal intraepithelial neoplasia (AIN) 19 (9.5%) 
7. Do you know the carcinogenic strains of HPV?     Specific strains 117 (58.5%) 
Don’t Know 83 (41.5%) 
8. Does HPV cause genital warts in women? 
a) Yes   
b) No  
c) Don’t Know 
 
a) 188 (94%) 
b) 9 (4.5%) 
c) 3 (1.5) 
9. Risk factors of cervical cancer include  
(a) Cervical infections including HPV, Chlamydia infection 
(b) Early age at first coitus  
(c) Multiparity  
(d) Family history  
(e) Poor hygiene  
(f) Smoking  
(g) Long-term use of oral contraceptives (birth control pills) 
(h) Being younger than 17 at your first full-term pregnancy 
(i) Being overweight 
 
a) 167 (83.5%) 
b) 33 (16.5%) 
c) 11 (5.5%) 
d) 88 (44%) 
e) 83 (41.5%) 
f) 32 (16%) 
g) 19 (9.5%) 
h) 68 (34%) 
i) 11 (5.5%) 
10. Technique for detection of HPV  
(a) pap smear  
(b) blood investigations  
(c) PCR  
 
a) 188 (94%) 
b) 27 (13.5%) 
c) 19 (9.5%) 
11. Is Cervical cancer preventable  
a) Yes  
b) No  
c) Don’t Know 
 
a) 126 (63%) 
b) 65 (32.5%) 
c) 9 (4.5%) 
 
The survey sample consisted of 200 medical students 
aged between 18‑25 years with a mean age of 21.8 ± 
1.57 years. There were 133 (66.5%) males and 67 
(33.5%) females studying in second or third year of 
M.B.B.S and all of them were unmarried. Almost all 
the students heard about of HPV. According to 198 
(96%) students, HPV infection spreads by sexual route 
but 41 (20.5%) said that it only spreads mother to 
newborn transmission. Eighty four percent of them 
answered that all cases of HPV infections progress to 
cervical cancer and 38% replied it may cause vulval 
and vaginal cancers in women. As replied by the 
participants the main hazards of HPV infections among 
women may be cervical, vulvar, vaginal, and anal 
cancer 49 (24.5%), genital warts (condyloma 
acuminata) 186 (93%), cervical intraepithelial 
neoplasia (CIN) and cervical adenocarcinoma in situ 
87(43.5%), vulvar intraepithelial neoplasia (VIN) 37 
(18.5%), vaginal intraepithelial neoplasia (VaIN) 23 
(11.5%), anal intraepithelial neoplasia 11 (5.5%). HPV 
infections among men may cause anal cancer 13 
(6.5%), genital warts (condyloma acuminata) 111 
(55.5%), and anal intraepithelial neoplasia (AIN) 19 
(9.5%). About 58.5% participants had recalled the 
carcinogenic strains of HPV. Students answered that 
the main risk factors of cervical cancer include cervical 
infections including HPV, chlamydia infection 167 
(83.5%), family history88 (44%), poor hygiene 83 
(41.5%) and being younger than 17 at your first full-
term pregnancy 68 (34%) etc. About 126 (63%) 
participants answered that cervical cancer is 
preventable whereas 65 (32.5%) replied negative 
[Table 1]. 
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Table 2: Attitude and knowledge of medical students towards HPV vaccination [n=200] 
1. Vaccine prevents other cancer 
a) Yes 
b) No 
c) Don’t Know 
 
a) 132 (66%) 
b) 62 (31%) 
c) 6 (3%) 
2. Vaccine prevent STDs 
a) Yes 
b) No 
c) Don’t Know 
 
a) 121 (60.5%) 
b) 68 (34%) 
c) 11(6.5%) 
3. Is the HPV vaccine available in India? 
a) Yes 
b) No 
c) Don’t Know 
 
a) 176 (88%) 
b) 17 (8.5%) 
c) 7 (3.5%) 
4. Is HPV vaccine part of a national program? 
a) Yes 
b) No 
c) Don’t Know 
 
a) 78 (39%) 
b) 89 (44.5%) 
c) 33 (16.5%) 
5. Can HPV vaccine be given to sexually active women? 
a) Yes 
b) No 
c) Don’t Know 
 
a) 189 (94.5%) 
b) 9 (4.5%) 
c) 2 (1%) 
6. Is Cervical cancer preventable 
a) Yes 
b) No 
c) Don’t Know 
 
a) 126 (63%) 
b) 65 (32.5%) 
c) 9 (4.5%) 
7. Age at which HPV vaccine should be given 
(a) 0-10 yrs 
(b) 11-30 yrs 
(c) 31-50 yrs 
a) 33 (16.5%) 
b) 156 (78%) 
c) 11 (5.5%) 
8. Number of HPV vaccine doses required for protection  
(a) one  
(b) two  
(c) three  
(d) four  
 
a) 68 (34%) 
b) 121 (60.5%) 
c) 11 (4.5%) 
d) 00 
9. The types of HPV vaccine available are  
(a) bivalent  
(b) quadrivalent  
(c) both  
(d) don’t know  
a) 29 (14.5%) 
b) 43 (21.5%) 
c) 115 (57.5%) 
d) 13 (6.5%) 
10. Schedule of HPV quadrivalent vaccine is  
(a) 0, 1 & 6 months  
(b) 0, 2 & 6 months  
(c) 1, 2 & 6 months  
(d) don’t know  
a) 47 (23.5%) 
b) 83 (41.5%) 
c) 51 (25.5%) 
d) 19 (8.5%) 
11. The route of administration of vaccine is  
(a) intramuscular  
(b) subcutaneous  
(c) intravenous  
(d) intradermal  
a) 123 (61.5%) 
b) 61 (30.5%) 
c) 00 
d) 16 (8%) 
12. The site of vaccination is  
(a) deltoid region of the upper arm  
(b) higher anterolateral area of the thigh 
(c) gluteal region  
(d) forearm 
(e) don’t know  
 
a) 127 (63.5%) 
b) 57 (28.5%) 
c) 16 (8%) 
d) 0 
e) 0 
13. The dose of vaccine is  
(a) 0.1 ml  
(b) 0.5 ml  
(c) 1.0 ml  
 
a) 57 (28.5%) 
b) 108 (54%) 
c) 35 (17.5%) 
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14. Cervical cancer protection provided by HPV vaccine is  
(a) 91-100%  
(b) 71-90 %  
(c) 51-70%  
(d) 31-50%  
(e) 10–30 % 
(f) Don’t Know 
 
 
a) 48 (24%) 
b) 27 (13.5%) 
c) 67 (33.5%) 
d) 28 (14%) 
e) 12 (6%) 
f) 18 (9%) 
15. Is it safe to have multiple sex partners after full course of HPV vaccine?  
(a)Yes  
(b) No  
(c) Don’t know 
 
a) 17 (8.5%) 
b) 176 (88%) 
c) 7 (3.5%) 
16. Would you like to receive HPV vaccine?  
(a) Yes  
(b) No  
(c) Don’t know  
 
a) 53 (26.5%) 
b) 136 (68%) 
c) 11 (5.5%) 
17. Who are eligible to take HPV vaccine? 
(a) girls and women 9 through 26 years of age 
(b) boys and women 9 through 26 years of age  
(c) both male & female 9 through 26 years of age 
(d) At any age 
(e) Don’t know 
 
a) 108 (54%) 
b) 27 (13.5%) 
c) 62 (31%) 
d) 03 (1.5%) 
e) 0 
 
18. Should only adolescent/pre-adolescent girls take HPV vaccine? 
(a) Yes  
(b) No  
(c) Don’t know 
 
a) 178 (89%) 
b) 18 (9%) 
c) 04 (2%) 
19. Are you vaccinated for HPV? 
(a) Yes  
(b) No  
(c) Don’t know 
 
a) 13 (6.5%) 
b) 177 (88.5%) 
c) 10 (5%) 
20. Do you know the names of HPV vaccines? 
(a) Yes  
(b) No 
 
a) 19 (9.5%) 
b) 181 (90.5%) 
21. What is the reason preventing you to receive or advice HPV vaccination?  
(a) High cost  
(b) Side effects  
(c) Doubt about effectiveness  
(d) Lack of access & knowledge  
 
 
a) 9 (4.5%) 
b) 11 (5.5%) 
c) 67 (33.5%) 
d) 113 (56.5%) 
22. Is the persistent HPV infection the cause of cervical cancer? 
a) Yes 
b) No 
c) Don’t Know 
 
a) 192 (96%) 
b) 7 (3.5%) 
c) 1 (0.5%) 
23. Can HPV vaccine effectively prevent genital warts of male? 
(a) Yes 
(b) No 
(c) Don’t know 
 
a) 113 (56.5%) 
b) 61 (30.5%) 
c) 26 (13%) 
24. Is HPV vaccines effectiveness on HPV infected person?  
a) Yes 
b) No 
c) Don’t know 
 
 
a) 45 (22.5%) 
b) 137 (68.5%) 
c) 18 (9%) 
25. Is screening necessary for HPV after receiving vaccine?  
(a)Yes  
(b) No  
(c) Don’t know  
 
 
a) 56 (28%) 
b) 134 (67%) 
c) 11 (5.5%) 
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Sixty six percent thought that it could protect against 
other cancers also and 60.5% expressed that HPV 
vaccine could protect against other sexually transmitted 
diseases. Eighty eight percent of the medical students 
were aware of availability of HPV vaccine in India. 
Only 39% answered that HPV vaccine is a part of 
National immunization program. About 189 (94.5%) 
students replied that HPV vaccine may be given to 
sexually active women. While evaluating the 
awareness regarding the target population for HPV 
vaccination, 92 participants 156 (78%) stated correctly 
as 11-30 years whereas 33 (16.5%) stated it as 0-10 
years and 11 (5.5%) as 31-50 years. As replied by 
participants HPV vaccine doses required for protection 
were one 68 (34%), two 121 (60.5%), three 11 (4.5%) 
and four nil respectively. The vaccination schedule is 
known correctly by minor fraction of participants. The 
types of HPV vaccine available are bivalent 29 
(14.5%), quadrivalent 43 (21.5%) or both 115 (57.5%). 
Majority of the participants (61.5%) mentioned 
intramuscular injection is used for HPV vaccine.  
About 63.5% students had mentioned deltoid region of 
the upper arm is the site for administering HPV 
vaccine. Out of 200 medical student participants only 
13 (6.5%) were vaccinated with HPV vaccines. None 
of the male student was vaccinated with HPV. Ninety 
six percent students answered that persistent HPV 
infection the cause of cervical cancer. One hundred 
thirteen (56.5%) students had replied HPV vaccine 
effectively prevent genital warts of male. 
Approximately 22.5% students answered that HPV 
vaccines may show effectiveness on HPV infected 
person. About 67% students agreed that there is need 
of screening after receiving HPV vaccination. Majority 
of the students 181 (90.5%) didn’t know the names of 
HPV vaccine. Correct dose (0.5 ml) of one vaccine was 
replied by 54% of the study participants. Cervical 
cancer protection provided by HPV vaccine was 
assumed 91-100% in 24% followed by 51-70% 
(13.5%) study participants. The reasons for preventing 
you to receive or advice HPV vaccination were high 
cost (4.5%), side effects (5.5%), doubt about 
effectiveness (33.5%) and lack of access & knowledge 
(56.5%). About 136 (68%) medical students positively 
had shown their interest for taking HPV vaccination 
[Table 2]. 
 
Table 3: Health-belief variables, HPV infection/vaccine knowledge, and intention to obtain [n=200] 
1. Source of information for you on HPV vaccine  
a) Textbooks  
b) Classrooms teaching  
c) Internet  
d) News paper & TV  
e) Friends 
 
a) 188 (94%) 
b) 87 (43.5%) 
c) 62 (31%) 
d) 21 (10.5%) 
e) 9 (4.5%) 
2. Would you like to update your knowledge about HPV vaccine by experts?  
(a) Yes  
(b) No  
 
a) 198 (99%) 
b) 2 (1%) 
3. HPV vaccine does not eliminate the necessity for women to continue to 
undergo recommended cervical cancer screening. 
(a) Yes  
(b) No 
(c) Don’t know  
 
a) 87 (43.5%) 
b) 91 (45.5%) 
c) 22 (11%) 
4. Recipients of HPV vaccine should not discontinue anal cancer screening 
if it has been recommended by a health care provider.  
(a) Yes 
(b) No 
(c) Don’t know 
 
 
a) 103 (51.5%) 
b) 80 (40%) 
c) 17 (8.5%) 
5. HPV vaccine has not been demonstrated to provide protection against 
disease from vaccine and non-vaccine HPV types to which a person has 
previously been exposed through sexual activity.  
(a) Yes 
(b) No 
(c) Don’t know 
 
 
a) 45 (22.5%) 
b) 137 (68.5%) 
c) 18 (9%) 
6. HPV vaccine is not intended to be used for treatment of active external 
genital lesions; cervical, vulvar, vaginal, and anal cancers; CIN; VIN; 
VaIN, or AIN.  
(a) Yes 
(b) No 
(c) Don’t know 
 
a) 128 (64%) 
b) 45 (22.5%) 
c) 27 (13.5%) 
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7. HPV vaccine has not been demonstrated to protect against diseases due to 
HPV types not contained in the vaccine.  
(a) Yes 
(b) No 
(c) Don’t know 
 
a) 157 (78.5%) 
b) 34 (17%) 
c) 09 (4.5%) 
 
Majority of the students (52%) thought lack of access 
and knowledge was the most important obstacle for 
receiving HPV vaccination followed by doubt about 
effectiveness. The most common source of information 
for our study population was teachers and textbooks 
(94%) followed by classroom teaching 43.5%. Other 
sources of information include internet (31%), news 
papers and television (10.5%) and friends (4.5%). 
Majority of the study group (99%) like to update their 
knowledge by experts. About 14.2% of our study 
participants had been questioned by friends and 
relatives regarding HPV vaccination. About 43.5% 
participants agreed that HPV vaccine does not 
eliminate the necessity for women to continue to 
undergo recommended cervical cancer screening. 
Approximately 51.5% student participants had replied 
that recipients of HPV vaccine should not discontinue 
anal cancer screening if it has been recommended by a 
health care provider. Sixty four percent of study 
participants agreed that HPV vaccine is not intended to 
be used for treatment of active external genital lesions; 
cervical, vulvar, vaginal, and anal cancers; CIN; VIN; 
VaIN, or AIN. About 78.5% study participants 
answered that HPV vaccine has not been demonstrated 
to protect against diseases due to HPV types not 
contained in the vaccine [Table 3]. 
 
DISCUSSION 
 
Sexually transmitted human papilloma virus (HPV) 
infection is the most important risk factor for cervical 
intraepithelial neoplasia and invasive cervical cancer. 
[9] HPV transmission is influenced by sexual activity 
and age. Almost 75% of all sexually active adults are 
likely to be infected with at least one HPV type. 
However, vast majority of the infections resolve 
spontaneously and only a minority (<1%) of the HPV 
infections progress to cancer. The lifetime risk for 
genital HPV is 50–80% and genital warts is 
approximately 5%. [10,11] The Pap test is used to find 
cellular abnormalities in cervical tissue, aiding early 
diagnosis. HPV is a necessary cause of cervical cancer, 
but it is not a sufficient cause. Other cofactors are 
necessary for progression from cervical HPV infection 
to cancer. Long-term use of hormonal contraceptives, 
high parity, early initiation of sexual activity, multiple 
sex partners, tobacco smoking and co-infection with 
HIV have been identified as established cofactors; co-
infection with Chlamydia trachomatis and herpes 
simplex virus type-2, immunosuppression, low 
socioeconomic status, poor hygiene and diet low in 
antioxidants are other probable cofactors. Genetic and 
immunological host factors and viral factors such as 
variants of type, viral load and viral integration are 
likely to be important, but have not been clearly 
identified[10,12].Two vaccines licensed globally are 
available in India; a quadrivalent vaccine (Gardasil™ 
marketed by Merck) and a bivalent vaccine 
(Cervarix™ marketed by Glaxo Smith Kline). These 
vaccines do not protect against the serotype with which 
infection has already occurred before vaccination[13]. 
HPV vaccine is not licensed for use among males. 
Gardasil™ is a mixture of L1 proteins of HPV 
serotypes 16, 18, 6 and 11 with aluminum-containing 
adjuvant. This vaccine confers protection against both 
cervical cancer and genital warts. Cervarix™ is a 
mixture of L1 proteins of HPV serotypes 16 and 18 
with AS04 as an adjuvant. This vaccine confers 
protection only against cervical cancer[13].The 
bivalent and quadrivalent vaccines available are 
prophylactic, not therapeutic. About 99–100% efficacy 
was reported against vaccine-type related genital warts, 
vaginal intraepithelial neoplasia and vulvar 
intraepithelial neoplasia. The vaccine dose is 0.5 mL 
given intramuscularly, either in the deltoid muscle or in 
the antero-lateral thigh. It is available as a sterile 
suspension for injection in a single-dose vial or a 
prefilled syringe, which should be shaken well before 
use. The recommended age for initiation of vaccination 
is 9–12 years. Catch-up vaccination is permitted up to 
the age of 26 years. A total of three doses at 0, 2 and 6 
months are recommended with Gardasil™ or 0, 1 and 6 
months with Cervarix™ (minimum interval of 4 weeks 
between the first and the second dose, 12 weeks 
between the second and third dose and 24 weeks 
between the first and third dose)[10]. Vaccines are not 
100% protective against cervical cancer and not a 
replacement for periodic screening. Hence, screening 
programs should continue as per recommendations. 
Cervical cancer ranks as the 2nd leading cause of 
female cancer in India. Cervical cancer is the 2nd most 
common female cancer in women aged 15 to 44 years 
in India. Women have higher incidences of anal cancer 
than men. Quadrivalent HPV vaccine is administered 
intramuscularly as three separate 0.5-mL doses. The 
second dose should be administered 2 months after the 
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first dose and the third dose 6 months after the first 
dose. The vaccine is available as a sterile suspension 
for injection in a single-dose vial or a prefilled syringe. 
[14]Most of the participants in our study were well 
aware of the viral etiology and preventable nature of 
cervical cancer. Similar finding was observed by 
Pandey et al[15] and Mehta et al[16] while Saha et al[17] 
reported a very low level of awareness among the 
female students of premier colleges in Kolkata. S 
Mehta et al reported that 66.8% were willing to accept 
the HPV vaccine[16] and Snigdha Kamini et al[17] 
findings (64%) come close to this. Females were more 
willing to accept vaccination. Majority of students said 
that lack of adequate knowledge was the most 
important factor preventing them from getting 
vaccinated. This is consistent with several other studies 
in India, another main reason being high cost. 
Sufficient scientific evidence has clarified many of the 
misunderstandings related to vaccine safety, however, 
the concerns related to vaccination are still increasing. 
[18,19]In developing countries like India where HPV 
infection is high, introducing a national HPV 
vaccination programme may reduce the incidence of 
cervical cancer. The Indian Academy of Pediatrics 
Committee on Immunisation (IAPCOI) recommends 
offering HPV vaccine to all females who can afford the 
vaccine. [20]In Kamini S et al (2016) study, 64.9% were 
willing to receive/ advice HPV vaccination. The others 
were either unsure or unwilling. 80.8% of females were 
willing to receive vaccination while only 44% of males 
were willing to advice it to women. The most 
important factor that deterred the subjects from 
receiving/advising HPV vaccination was lack of 
enough knowledge, followed by high cost and then fear 
of complications. The most important source of 
knowledge was Medical education. [17]According to 
Challa N et (2011) the most common source of 
information for our study population was teachers and 
textbooks (59.8%). Other sources of information 
include internet (17.3%), news papers and television 
(14.2%) and friends (8.7%). Majority of the study 
group (92.9%) like to update their knowledge by 
experts. About 14.2% of our study participants had 
been questioned by friends and relatives regarding 
HPV vaccination. [21] The success and benefit of 
control and prevention of cervical cancer largely 
depend to a great extent on the level of awareness and 
knowledge about different aspects of the disease and 
the vaccine. It is therefore important to target 
immunizable young adult college-going girls and boys, 
as both are part of the infection chain and at risk for 
HPV infection as they are living a more independent 
lifestyle but have a choice to undergo vaccination with 
the consent from parents and are within the age group 
of successful vaccination outcome. Hence, assessment 
of their knowledge, awareness and attitude towards the 
causes of cervical cancer, HPV infection and 
vaccination available for the disease including 
adequate participation in immunization programs can 
lead to successful reduction in disease burden and 
control of cervical cancer in India.[22] 
 
CONCLUSION 
 
Human papillomavirus infection is now a well-
established cause of cervical cancer and there is 
growing evidence of HPV being a relevant factor in 
other anogenital cancers (anus, vulva, vagina and 
penis) as well as head and neck cancers. Male 
circumcision and the use of condoms have shown a 
significant protective effect against HPV transmission. 
The results of this study show the importance and 
necessity of medical teaching to focus on upcoming 
issues like HPV vaccine. This clearly demonstrates the 
gap in knowledge. Overcoming this gap is necessary if 
we want to decrease the burden of cervical cancer in 
India. It is suggested that there is a need for educational 
intervention and awareness campaigns to augment 
HPV immunization program for control of cervical 
cancer in India. 
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